Heather Schott
Adult Health · Wentzville, MONPI 1730757139
Payments from drug & device makers
Across 122 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$340
- Novo Nordisk$314
- AstraZeneca$212
- AbbVie$158
- Lilly USA, LLC$152
- Boehringer Ingelheim$119
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,350100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $340 |
| Novo Nordisk | 18 | $314 |
| AstraZeneca(2 entities) | 9 | $212 |
| AbbVie | 7 | $158 |
| Lilly USA, LLC | 7 | $152 |
| Boehringer Ingelheim | 7 | $119 |
| Exact Sciences | 6 | $112 |
| Johnson & Johnson | 5 | $112 |
| Sumitomo Pharma America, Inc. | 5 | $81 |
| Teva Pharmaceuticals USA, Inc. | 5 | $80 |
| Pfizer | 4 | $68 |
| Neurocrine Biosciences, Inc. | 2 | $54 |
| GSK | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Lundbeck LLC | 2 | $46 |
| Astellas Pharma US Inc | 2 | $44 |
| Dexcom, Inc. | 2 | $41 |
| Globus Medical | 2 | $38 |
| Neurelis, Inc. | 2 | $34 |
| Abbott | 2 | $32 |
| Verona Pharma, Inc. | 1 | $29 |
| Eisai Inc. | 1 | $28 |
| Radius Health, Inc. | 1 | $28 |
| Bayer | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$2,350 in reported general payments places this provider in the 75th percentile of 555 adult health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $29,154 |
| FarxigaDapagliflozin Propanediol | 19 | $12,736 |
| EliquisApixaban | 20 | $11,918 |
| GemtesaVibegron | 24 | $10,831 |
| MyrbetriqMirabegron | 16 | $7,597 |
| JanuviaSitagliptin Phosphate | 12 | $7,443 |
| Methenamine Hippurate | 11 | $1,208 |
| Midodrine Hcl | 12 | $1,055 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $988 |
| Omeprazole | 63 | $829 |
| Sertraline Hcl | 60 | $818 |
| Ondansetron Hcl | 21 | $800 |
| Pantoprazole Sodium | 58 | $775 |
| Gabapentin | 77 | $755 |
| Fluticasone Propionate | 44 | $730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $314 | $29,15429 claims |
| AstraZenecaFarxiga | $212 | $12,73619 claims |
| PfizerEliquis | $68 | $11,91820 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $81 | $10,83124 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $7,59716 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $81860 claims |
| Lilly USA, LLCOlanzapine | $152 | $15114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 555 adult health providers in Missouri.
Other adult health in Wentzville
- Tabitha StithChesterfield$300K
- Stephanie VogelSaint Louis$115K
- Racquel FrisellaChesterfield$110K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Katie MurrayIndependence$59K
- Patrick BehnkeChesterfield$54K
- Elaine ZobristFenton$38K
- Yolanda Thompson MartinKansas City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.